

Adamis Pharmaceuticals Corporation
11683 El Camino Real, Suite 300
San Diego, CA 92103

July 28, 2023

VIA EDGAR

Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549

**Re: Adamis Pharmaceuticals Corporation
Registration Statement on Form S-3 (No. 333-273233)
Filed on July 13, 2023
Withdrawal of Request for Acceleration**

To Whom it May Concern:

Adamis Pharmaceuticals Corporation (the "Company") hereby requests the withdrawal of our request for acceleration, dated July 26, 2023, of the effective date of the above referenced registration statement as amended (the "Registration Statement") (File No. 333-273233) that was requested to become effective at 9:00 a.m. Eastern Time, on July 28, 2023, or as soon thereafter as practicable. We hereby respectfully withdraw this acceleration request at this time. Should any member of the staff of the Commission have any questions or comments with respect to this request, please contact Kevin Kelso at Weintraub Tobin, our counsel, at (916) 558-6110.

Very truly yours,

Adamis Pharmaceuticals Corporation

By: /s/ David J. Marguglio
David J. Marguglio
President
